Next Article in Journal
Phytomedicine in Otorhinolaryngology and Pulmonology: Clinical Trials with Herbal Remedies
Next Article in Special Issue
The Use of California Sagebrush (Artemisia californica) Liniment to Control Pain
Previous Article in Journal
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
Previous Article in Special Issue
Receptor and Channel Heteromers as Pain Targets
Open AccessReview

Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases

Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma, Nara 630-0101, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(8), 837-852; https://doi.org/10.3390/ph5080837
Received: 29 June 2012 / Revised: 2 August 2012 / Accepted: 15 August 2012 / Published: 17 August 2012
(This article belongs to the Special Issue Emerging Pain Targets and Therapy)
Transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is a receptor activated by high temperatures and chemical agonists such as the vanilloids and protons. Because of these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. TRPV1 is thought to be a central transducer of hyperalgesia and a prime target for controlling pain pharmacologically because it is a point where many proalgesic pathways converge and it is upregulated and sensitized by inflammation and injury. However, whether TRPV1 agonists promote or inhibit inflammation remains unclear. We recently demonstrated that SA13353 (1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea), a novel TRPV1 agonist, inhibits tumor necrosis factor-a production by the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms in kidney injury, lung inflammation, arthritis, and encephalomyelitis. These results suggest that TRPV1 agonists may act as anti-inflammatories in certain inflammatory and autoimmune conditions in vivo. Given the potential deleterious effects of inhibiting the population of channels with a protective function, caution should be taken in the use of potent TRPV1 antagonists as a general strategy to treat inflammation. Further studies are required to clarify the role of TRPV1 and neuropeptides, which are released because of TRPV1 activation in inflammation and autoimmune diseases. View Full-Text
Keywords: SA13353; transient receptor potential vanilloid 1; kidney injury; lung inflammation; autoimmune diseases; pain SA13353; transient receptor potential vanilloid 1; kidney injury; lung inflammation; autoimmune diseases; pain
Show Figures

Figure 1

MDPI and ACS Style

Tsuji, F.; Aono, H. Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases. Pharmaceuticals 2012, 5, 837-852.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop